To the Editor:

Extensively drug-resistant (XDR) tuberculosis (TB) is a type of multidrug-resistant (MDR) TB that is resistant to isoniazid, rifampicin, fluoroquinolones and at least one injectable second-line drug. There are insufficient antibiotics for effective combination therapy and mortality exceeds 70% \[[@C1]\]. Following successful phase IIb trials \[[@C2]\] in 2013, the novel mycobacterial ATP-synthase inhibitor bedaquiline was approved in Europe and the USA for the first 24 weeks of MDR/XDR-TB treatment alongside a World Health Organization (WHO)-approved optimised background regimen. Phase III trials are ongoing but cohort data describe good early bacteriological outcomes in France \[[@C3], [@C4]\], Italy \[[@C5]\], the UK \[[@C6]\], the USA \[[@C7]\], India \[[@C8]\] and South Africa \[[@C9]\].

However, WHO guidelines presently advocate a total MDR/XDR-TB treatment duration of ≥18 months. In the presence of extensive resistance, antibiotic regimens may be sparse when bedaquiline is stopped. The US Centers for Disease Control and Prevention (CDC) recommend continuing bedaquiline beyond 24 weeks if effective treatment "cannot otherwise be provided", whilst acknowledging the lack of supporting tolerability data \[[@C10]\]. Although no fatalities in pre-licensing studies were attributed to the study drug, there were more deaths on bedaquiline than placebo (10 *versus* two) \[[@C2]\]. The plasma half-life of bedaquiline is 4--5 months and corrected QT interval (QTc) prolongation occurs, raising concerns about incremental toxicity and highlighting the need for expedient reporting of clinical experience. Here, we describe the first published case of safe bedaquiline treatment extension to 18 months in a patient with pulmonary XDR-TB.

In January 2014, a 20-year-old, HIV-negative Romanian woman was referred to our unit with a first presentation of smear-positive pulmonary TB. Computed tomography (CT) scans showed multifocal disease of both lungs. She had no comorbidities and was initiated on first-line antituberculous chemotherapy (rifampicin, isoniazid, pyrazinamide and ethambutol) but after 2 days, the Genotype MDRTB*plus* 2.0 assay (Hain Diagnostics, Cookville, TN, USA), performed on the patient\'s sputum sample, revealed *rpoB* and *katG* mutations consistent with rifampicin and isoniazid resistance. Therefore, she was switched to a WHO-approved MDR-TB regimen ([figure 1](#F1){ref-type="fig"}). During February, full phenotypic drug susceptibility testing and whole-genome sequencing revealed extensive resistance to all first-line drugs, all quinolones, all injectables and prothionamide. Susceptibilities to linezolid, para-aminosalicylic acid (PAS) and azithromycin were confirmed. Phenotypic sensitivity testing to meropenem/imipenem and clofazimine were unavailable, but whole-genome sequencing was performed and identified *katG* mutations conferring high-level isoniazid resistance, precluding the use of high-dose isoniazid. At week 8 of treatment, she was established on a six-drug regimen of bedaquiline, linezolid, pyrazinamide, cycloserine, azithromycin and PAS. Bedaquiline was obtained through a compassionate use programme and introduced at 400 mg once daily for 2 weeks, followed by 200 mg three times weekly. [Figure 1](#F1){ref-type="fig"} illustrates progression of her regimen as resistance information became available and throughout the remainder of therapy. Her sputum converted to smear and culture negative 24 days after initiation of the bedaquiline based regimen, and 81 days after starting first-line treatment.FIGURE 1a) Drug regimen, sputum smear and culture status, and b) corrected QT interval (QTc) of the patient by week. Horizontal dashed lines represent median QTc between 12 and 39 weeks (425 ms) and 40--93 weeks (472 ms). P: positive sputum smear/culture; N: negative smear/culture; R: rifampicin; H: isoniazid; Z: pyrazinamide; E: ethambutol; Am: amikacin; Mfx: moxifloxacin; Cs: cycloserine; Pro: prothionamide, Lz: linezolid; Cm: capreomycin; BDQ: bedaquiline; PAS: para-aminosalicylic acid; Azith: azithromycin; Cfz: clofazimine; MDR: multidrug-resistant.

She successfully completed her initial supply of bedaquiline. Between week 32 and 34, she developed painful peripheral neuropathy, confirmed on nerve conduction studies, which prompted discontinuation of linezolid and cycloserine. After discussion with the British Thoracic Society MDR-TB advisory panel and international experts, her remaining regimen was deemed inadequate and her bilateral pulmonary disease excluded surgical management. Therefore, clofazimine was introduced at week 32 and bedaquiline was restarted, at a dose of 200 mg three times weekly, at week 38.

ECGs were reviewed by a consultant cardiologist regularly during bedaquiline administration. [Figure 1](#F1){ref-type="fig"} shows changes to the QTc interval over time. Initially, whilst the patient was admitted to hospital, ECGs were performed weekly, then less frequently (weekly, biweekly or monthly as directed by the cardiologist) once she was discharged; however, there were occasional periods where, due to financial or transportation problems, the patient failed to attend an ECG appointment, which is reflected in occasional periods of several weeks between ECGs in [figure 1](#F1){ref-type="fig"}. From a pre-treatment baseline of 411 ms, the QTc increased to 465 ms at week 10 before settling to a median of 425 ms between weeks 12 and 40. There was a steep rise in QTc after week 40 (during bedaquiline, clofazimine and azithromycin co-administration). Azithromycin was stopped at week 62, QTc peaked at 495 ms in week 68 and the median QTc from week 40 until the end of therapy was 472 ms. Serum potassium, magnesium and corrected calcium concentrations were always within normal limits, and care was taken to avoid QTc prolonging agents other than those required for TB therapy. T-wave inversion in the ECG anterior leads was also noted, though cardiac troponins were normal and the patient reported no cardiac symptoms. No cardiac arrhythmias or other adverse clinical events were reported.

Bedaquiline treatment was continued for a total of 72 weeks (18 months). With no recurrence of sputum smear or culture positivity, gradual weight gain and resolution of active inflammatory changes on serial CT scans, the patient is now regarded as cured. Post-treatment follow-up will continue to ensure there is no relapse.

This case describes that bedaquiline administration may be safely extended beyond 6 months, which is an important consideration when balancing the terrible prognosis of XDR-TB against the uncertain efficacy and safety of new antibiotics. The recognised global burden of drug-resistant TB increased from 250 000 incident cases in 2009 to 480 000 cases in 2014 \[[@C11]\]. In Eastern Europe, over 20% of new TB patients present with MDR or XDR disease \[[@C11]\] and our patient demonstrates the increasingly frequent therapeutic challenges posed by this problem.

Antibiotic options in XDR-TB are always limited to drugs of uncertain efficacy. Of the available agents, the impressive bactericidal activity of bedaquiline in phase II clinical studies \[[@C2]\] offers considerable promise. However, current experience and licencing of bedaquiline is limited to administration for 24 weeks of a total of 18--24 months treatment duration \[[@C12], [@C13]\]. This will inevitably generate case management dilemmas when XDR-TB patients are left with sparse regimens for most of their therapy. To minimise the risk of eventual failure or relapse, it seems desirable to continue the most potent agents for longer and CDC guidelines allow extension of bedaquiline treatment on a case-by-case basis \[[@C10]\]. To our knowledge, our case is the first published description of that approach.

A major concern with prolonged bedaquiline use is the risk of toxicity. QTc interval prolongation is regarded as the most significant adverse effect \[[@C13]\] and we observed this, particularly when bedaquiline was administered with other known QTc prolonging agents (clofazimine and azithromycin). Nevertheless, given the high likelihood of mortality from XDR-TB treatment failure, we sought specialist cardiology input for treatment monitoring and persisted with bedaquiline. The therapeutic response was favourable and there were no clinical side-effects. It is noteworthy that our patient was young and previously well; greater caution may be required in older patients with cardiac comorbidities.

Trials are ongoing to establish whether MDR-TB therapy can be shortened to 9 months \[[@C14]\] and some of these studies include bedaquiline-based regimens \[[@C15]\]. However, it will be several years until results are available. In the meantime, clinical use of novel antituberculous drugs and combination regimens will be informed by incremental experience from case reports and case series. In this scenario, our experience that bedaquiline can be safe and effective when continued for up to 18 months in the treatment of pulmonary XDR-TB is important and relevant for other clinicians managing drug-resistant TB.
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